Menopur (Menotrophin)

Menotropin contains both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). These hormones bind to specific receptors on ovarian cells, promoting granulosa cell proliferation, estradiol synthesis, and the maturation of ovarian follicles, ultimately leading to ovulation when used in fertility protocols.

The dose of Menopur is individualized and set by the prescribing clinician based on the patient’s ovarian reserve, response to prior stimulation, and the specific assisted reproduction protocol. Patients should follow the exact dosing instructions provided by their fertility specialist.

Menopur is not intended for use during pregnancy, and its safety in pregnant women has not been established. Women should avoid becoming pregnant while receiving Menopur until the treatment cycle is completed. Limited data are available regarding excretion in breast milk, so breastfeeding is generally not recommended during treatment.

To order Menopur, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. After verification, the team provides pricing, availability, shipping details (including cold‑chain handling if needed) and assists with import documentation.

Menopur provides a combination of FSH and LH activity in a single preparation, whereas some alternatives such as recombinant FSH (e.g., follitropin alfa) contain only FSH. The combined activity can be advantageous for patients with LH deficiency, but individual response varies, and clinicians choose the product based on patient profile and protocol requirements.

Menopur should be stored at 2‑8 °C in a refrigerator, protected from light. The vial must not be frozen or shaken. Once reconstituted, it should be used within the time frame specified in the product labeling and kept at controlled room temperature if required for a short period.

Menopur is supplied as a powder for solution for injection. After reconstitution with the appropriate diluent, it is administered subcutaneously, typically in the abdominal wall or thigh, according to the dosing schedule prescribed by the fertility specialist.

The most serious risks include ovarian hyperstimulation syndrome (OHSS), which can be mild to severe, and the possibility of multiple pregnancy. Rare but severe reactions such as anaphylaxis, thromboembolic events, or severe abdominal pain should prompt immediate medical evaluation.

Menopur should not be used in women who are already pregnant, have known hypersensitivity to menotropin or any excipients, or have uncontrolled endocrine disorders that could be aggravated by gonadotropin therapy. Caution is also advised for patients with ovarian cysts, severe ovarian disease, or a history of thromboembolic events.